Clinical trials update: highlights of the scientific sessions of the American heart association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure
Sdr. Thackray et al., Clinical trials update: highlights of the scientific sessions of the American heart association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure, EUR J HE FA, 3(1), 2001, pp. 117-124
This article continues a series of reports summarising recent research deve
lopments pertinent to the topic of heart failure. This is a summary of pres
entations made at scientific sessions of the American Heart Association in
November 2000. Clinical studies of particular interest to people caring for
patients with heart failure include Val-HeFT, AMIOVIRT and V-MAC. New data
from beta -blockers trials are reviewed, highlights from some important de
velopments in post-infarction care, including MIRACL and FLORIDA, discussed
and results of some early studies of gene therapy reported. (C) 2001 Europ
ean Society of Cardiology All rights reserved.